文献速递前列腺癌

ProCUSNet:基于人工智能的B型经直肠超声前列腺癌检测用于前列腺穿刺靶向

ProCUSNet: Prostate Cancer Detection on B-mode Transrectal Ultrasound Using Artificial Intelligence for Targeting During Prostate Biopsies.
PubMed 文献 · Eur Urol Oncol · 2025-01-28

本研究纳入两家机构2986例接受穿刺的男性,训练ProCUSNet在B型经直肠超声图像上检测临床显著前列腺癌。ProCUSNet检出82%的临床显著癌,病灶边界误差达2.67 mm,检出病灶数比超声阅读者多42%(敏感度0.86 vs 0.44,p<0.05),与MRI放射科医生性能相似(敏感度0.79 vs 0.78,p>0.05)。

要点

  • ProCUSNet在B型经直肠超声上检出82%的临床显著癌,病灶边界误差达2.67 mm。
  • ProCUSNet检出病灶数比超声阅读者多42%(敏感度0.86 vs 0.44,p<0.05)。
  • ProCUSNet与MRI放射科医生性能相似(敏感度0.79 vs 0.78,p>0.05),可作为系统穿刺的补充。

核心结论

  • ProCUSNet可在屏幕截取的B型超声上定位临床显著癌,作为系统穿刺的补充,其表现与MRI相当,可能有助于穿刺时靶向可疑病灶,并可能用于无MRI时单独超声筛查。

研究设计与样本

  • 研究纳入两家机构2986例接受穿刺的男性,训练基于nnUNet框架的ProCUSNet,在从2D屏幕截图重建的3D检查上检测并勾勒临床显著癌。
  • ProCUSNet与参考标签(n=515例患者)、8名解读B型超声的阅读者(n=20-80例患者)以及为临床诊疗解读MRI的放射科医生(n=110例根治性前列腺切除术患者)进行比较。

主要发现

  • ProCUSNet检出82%的临床显著癌病例,病灶边界误差达2.67 mm。
  • ProCUSNet检出病灶数比超声阅读者多42%(敏感度0.86 vs 0.44,p<0.05,Wilcoxon检验,Bonferroni校正)。
  • ProCUSNet与解读MRI的放射科医生性能相似(敏感度0.79 vs 0.78,p>0.05,Wilcoxon检验,Bonferroni校正),同时作为系统穿刺的补充具有相同的靶向效用。

临床怎么用

  • 作者认为,ProCUSNet作为系统穿刺的补充,表现与MRI相当,提示其可用于穿刺时靶向可疑病灶,并可能用于无MRI时单独超声筛查。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: To assess whether conventional brightness-mode (B-mode) transrectal ultrasound images of the prostate reveal clinically significant cancers with the help of artificial intelligence methods. METHODS: This study included 2986 men who underwent biopsies at two institutions. We trained the PROstate Cancer detection on B-mode transrectal UltraSound images NETwork (ProCUSNet) to determine whether ultrasound can reliably detect cancer. Specifically, ProCUSNet is based on the well-established nnUNet frameworks, and seeks to detect and outline clinically significant cancer on three-dimensional (3D) examinations reconstructed from 2D screen captures. We compared ProCUSNet against (1) reference labels (n = 515 patients), (2) eight readers that interpreted B-mode ultrasound (n = 20-80 patients), and (3) radiologists interpreting magnetic resonance imaging (MRI) for clinical care (n = 110 radical prostatectomy patients). KEY FINDINGS AND LIMITATIONS: ProCUSNet found 82% clinically significant cancer cases with a lesion boundary error of up to 2.67 mm and detected 42% more lesions than ultrasound readers (sensitivity: 0.86 vs 0.44, p < 0.05, Wilcoxon test, Bonferroni correction). Furthermore, ProCUSNet has similar performance to radiologists interpreting MRI when accounting for registration errors (sensitivity: 0.79 vs 0.78, p > 0.05, Wilcoxon test, Bonferroni correction), while having the same targeting utility as a supplement to systematic biopsies. CONCLUSIONS AND CLINICAL IMPLICATIONS: ProCUSNet can localize clinically significant cancer on screen capture B-mode ultrasound, a task that is particularly challenging for clinicians reading these examinations. As a supplement to systematic biopsies, ProCUSNet appears comparable with MRI, suggesting its utility for targeting suspicious lesions during the biopsy and possibly for screening using ultrasound alone, in the absence of MRI.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Rusu M, Jahanandish H, Vesal S, et al. ProCUSNet: Prostate Cancer Detection on B-mode Transrectal Ultrasound Using Artificial Intelligence for Targeting During Prostate Biopsies. Eur Urol Oncol. 2025. PMID: 39880746. doi:10.1016/j.euo.2024.12.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。